Sir, Over the last decade, the importance of fungal organisms as allergens has increased. Allergic bronchopulmonary aspergillosis (ABPA) is an inflammatory disease of the airways caused by hypersensitivity to the Aspergillus fumigatus antigen and occurs in $1% of asthmatics and 15% of adult cystic fibrosis patients. The widespread use of itraconazole for the treatment of ABPA has been reported to improve lung function and aid in reducing the concentration of glucocorticosteroids required. 1 Other manifestations of fungal allergy of the respiratory tract include allergic fungal sinusitis and severe asthma with fungal sensitization (SAFS). 2 Recently, a randomized placebo-controlled study of itraconazole treatment of SAFS has shown major improvements in asthmatic control and quality of life in patients sensitized to one of several fungi including Penicillium, Cladosporium and others. 2 These data and the introduction of the new azole drugs voriconazole and posaconazole led us to examine the azole susceptibility of other potentially allergenic moulds. 3 In this study, the in vitro activity of posaconazole and voriconazole is compared with that of itraconazole.
Eighteen mould isolates were evaluated: two Alternaria alternata, two Botrytis cinerea, one Cladosporium cladosporioides, two Cladosporium herbarum, two Epicoccum purpurascens, one Helminthosporium halodes, two Helminthosporium maydis, two Penicillium chrysogenum, two Trichophyton interdigitale and two Trichophyton rubrum. Eleven isolates were obtained from the culture collection at Centraalbureau voor Schimmelcultures (CBS), the Netherlands, and both C. herbarum and one E. purpurascens were environmental isolates (identified by CBS). All Trichophyton spp. were clinical isolates from the culture collection at The Regional Mycology Laboratory, Manchester, UK.
MICs were determined according to CLSI (formerly NCCLS) M38-A guidelines, 4 with modified temperature and length of incubation (due to growth requirements of organisms being tested). Final drug concentrations ranged from 0.015 to 8 mg/L.
Isolates were grown on Sabouraud agar at either room temperature or 308C, and inocula were prepared in PBS containing 0.05% Tween 80. A spectrophotometric method for inoculum preparation was used for all isolates, except Penicillium (counted by a haemocytometer). Plates were incubated at room temperature or 308C for durations of 2-8 days, depending on the organism tested, in a moist chamber. Plates were checked daily and read when sufficient growth was apparent in the positive control, giving full well coverage (each species was read at the same incubation time). MICs were read visually to determine a no growth endpoint, and MFCs were also determined (99% kill).
The differences between drugs were analysed by a one-way analysis of variance with a Bonferroni correction for multiple comparisons (SPSS).
In general, the species tested had a susceptibility order of: posaconazole.itraconazole.voriconazole, with geometric mean MICs of 0.08, 0.16 and 1.21 mg/L, respectively (Table 1 ). All isolates had MICs of posaconazole that were lower or equal to those of itraconazole or voriconazole, except one Penicillium isolate, which had a lower MIC of itraconazole of 0.125 compared with an MIC of posaconazole of 0.25 mg/L. There was no significant difference (P .0.05) between MICs of posaconazole and itraconazole; however, significant differences (P,0.05) were seen between MICs of voriconazole and each of the other drugs.
Incubating P. chrysogenum at 308C instead of at room temperature mostly increased MICs of itraconazole and voriconazole, but no change was seen with posaconazole, suggesting that MIC values can be influenced by changes in incubation time and temperature at least for some drugs.
Using the CLSI M38-A guidelines for inoculum preparation, the colony counts for one-third of the isolates were not within the CLSI range, although each drug was tested simultaneously, enabling a valid comparison to be made.
Many studies have compared antifungal activity against filamentous fungi, but they cannot be directly compared with our results due to method differences. Furthermore, a small number of isolates were tested in this study. Cuenca-Estrella et al.
those obtained in our study. High MIC 90 values of itraconazole, posaconazole and voriconazole for Alternaria (all .8 mg/L) were also shown by Cuenca-Estrella et al., 5 but we only found this with voriconazole (2 and 8 mg/L). Susceptibility of Cladosporium species to itraconazole was investigated by Pujol et al., 6 and MICs obtained ranged from 0.035 to .20 mg/L (n ¼ 6), but we found that the three isolates tested were susceptible to itraconazole with MICs ranging from 0.06 to 0.25 mg/L.
All three azole drugs exhibited good activity against Trichophyton species (all MICs 0.5, except one T. rubrum isolate with an MIC of 1 mg/L). When using CLSI methods, previous studies have shown similar and also much higher MIC values of posaconazole and itraconazole compared with our findings.
MFCs were also determined in this study as it has been previously shown that they may correlate better with clinical outcomes than MICs. 7 We have demonstrated that all isolates were also killed by the drug concentration that inhibited them, except one isolate of T. rubrum. Sir, Streptococcus pneumoniae is the most common identifiable cause of community-acquired pneumonia. With the rise in resistance to penicillin and macrolides, other classes of antibiotics, notably the newer fluoroquinolones, are increasingly being used for the empirical treatment of pneumonia. As observed for other antibiotics, fluoroquinolone resistance has emerged in S. pneumoniae among sporadic isolates as well as in the major epidemic clones. 1 Our previous work documented the rapid emergence of pneumococcal resistance to the fluoroquinolones in Hong Kong since the late 1990s. 2, 3 This study assessed the recent epidemiology of levofloxacinresistant S. pneumoniae (LRSP) using the database of a clinical microbiology laboratory in Hong Kong. This laboratory provides service to a network of five hospitals, including one acute care university teaching hospital (HKW1) with 1400 beds and all the clinical disciplines and four chronic care hospitals (HKW2, HKW3, HKW4 and HKW5) with 110-524 beds. HKW4 only admits children. The hospital network is estimated to provide clinical service to a population of approximately 1 million. The data on S. pneumoniae from 2001 to 2007 were extracted, and duplicate isolates were removed by the initial isolate per patient method, irrespective of susceptibility and specimen source. Only the first isolate from each patient was included during the whole surveillance period. During this period, all isolates were routinely tested for their susceptibility to penicillin (oxacillin), erythromycin, co-trimoxazole, chloramphenicol and levofloxacin by the disc diffusion method. Penicillin MICs were determined by Etest (AB Biodisk, Solna, Sweden). All results were interpreted according to the CLSI. 4 Strains were identified as S. pneumoniae by Gram stain, colony morphology, optochin susceptibility and bile solubility.
